Researchers examined large-scale genomic datasets and found that patients with higher levels of miR-182 had a better chance of surviving glioblastoma (GBM) longer. This prompted them to perform pre-clinical studies to elucidate the mechanism by which miR-182 acts. Continue reading
![](http://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)